35 results about "Pulmonary inflammation" patented technology

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for treating acute respiratory distress syndrome and a preparation and a preparation method thereof, and the traditional Chinese medicine composition is prepared from the following raw materials: 12-30g of ginseng, 6-30 parts of rheum officinale, 9-30 parts of salvia miltiorrhiza and 3-15 parts of semen lepidii. Pharmacological experiments prove that the traditional Chinese medicine composition can improve lung inflammation infiltration to different degrees, improve lung tissue structure disorder and relieve pulmonary edema, and the clinical death rate is remarkably reduced in clinical application; the prepared preparation, especially granules, can be stored for 36 months for a long time, and is suitable for further industrial mass production.

The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (I), and sub-formulas thereof: Formula (I) or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatment or prevention of diseases including heart (e.g. ischemic heart disease, congestive heart failure, and valvular heart disease), lung (e.g., lung inflammation, pneumonia, acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), respiratory (e.g.,respiratory infection, acute respiratory distress syndrome), liver (e.g. acute liver failure and liver fibrosis and cirrhosis), and kidney (e.g. acute kidney injury and chronic kidney disease) disease, inflammatory bowel disease (IBD), ischemic reperfusion injury (e.g., stroke), retinopathy of prematurity (ROP), bronchopulmonary dysplasia (BPD), and white matter injury (WMI).

This invention discloses a class of pyrazolopyridine compounds linked by an aza-four-membered ring, or pharmaceutically acceptable salts thereof, and their applications. These compounds can serve as novel, highly selective PDE10A inhibitors for the treatment of peripheral tissue diseases, including: myocardial hypertrophy and cardiac dysfunction (heart failure), diabetes, hypertension, renal impairment and renal fibrosis, pulmonary inflammation and pulmonary fibrosis, immune dysregulation, and cancers (colon cancer, ovarian cancer, and lung cancer). Two strategies are employed to achieve high selectivity for PDE10A inhibition while simultaneously reducing the inhibitory effect on the central nervous system. First, molecular structure modification: structural optimization of the aza-four-membered ring-linked pyrazolopyridine compounds, such as increasing the ratio of N, O, and S atoms in the molecular structure to increase the polar surface area and reduce lipophilicity; and introducing hydrophilic groups to increase water solubility, thereby reducing the permeability of the compound to the blood-brain barrier (BBB). Second, targeted drug delivery to lung tissue via pharmaceutical formulation.

The application discloses a lung inflammation lesion quantitative evaluation artificial intelligence model based on CT images and relates to the field of artificial intelligence models.The model comprises CT image preprocessing, self-supervised lesion segmentation and quantification, multi-modal joint pre-training coding and multi-task diagnosis and prognosis prediction module composition which are sequentially and communicatively connected, and realizes feature interaction through a unified feature embedding space.The model realizes self-supervised lesion segmentation and multi-dimensional quantification by adopting a three-dimensional generative reconstruction network, completes image-text feature fine-grained alignment through cross-modal contrast learning of an adversarial enhancement, and fuses multi-dimensional features.The model can complete multiple tasks such as ARDS diagnosis, non-invasive estimation of P / F ratio, severity grading and prognosis prediction in parallel, reduces dependence on artificial labeling, improves cross-center generalization capability and diagnosis precision, and provides a standardized intelligent tool for clinical evaluation of severe lung inflammation.

The invention discloses a leonurine hydrochloride and ursolic acid self-assembled nano preparation and application thereof in preparation of a medicine for treating acute lung injury. The invention provides a leonurine and ursolic acid self-assembled nano-preparation. The leonurine and ursolic acid self-assembled nano-preparation is obtained by self-assembling leonurine pharmaceutically acceptable salts and ursolic acid, wherein the amounts of the leonurine pharmaceutically acceptable salts and the ursolic acid are equal. The self-assembled nanoparticles have an obvious anti-lung inflammation effect, and the anti-inflammatory effect is obviously superior to that of a composition of the leonurine pharmaceutically acceptable salt and ursolic acid with the same dosage. Therefore, the leonurine and ursolic acid self-assembled nano preparation provided by the invention has the prospect of being developed into the medicine for treating the acute lung injury.

The present disclosure provides compositions and methods for the treatment of coronavirus infections, such as SAR-CoV, SARS-CoV-2, and MERS-CoV. The compositions include antibodies targeting the IL-6 receptor complex, antibodies targeting CD3, dactinomycin, and combinations thereof. The methods of treatment include administration of antibodies and combination therapies to reduce or eliminate symptoms associated with coronavirus infection or pulmonary inflammatory disease.

The application discloses a RAP polypeptide analogue and medical use thereof, and belongs to the polypeptide medical field, and the amino acid sequence of the RAP polypeptide analogue is Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11-Xaa12-Xaa13-Xaa14-Xaa15-Xaa16-Xaa17, and the N terminal of the RAP polypeptide analogue is acetylated, and the C terminal amino acid is amidated. Compared with the natural RAP polypeptide, the analogue has higher stability, bioavailability and drug efficacy, meanwhile, the dosage is low, the toxic and side effects are not obvious, the production cost is low, and the analogue has good popularization and clinical application prospects. The analogue is suitable for preventing and treating acute and chronic nephritis, chronic nephropathy and renal fibrosis caused by the acute and chronic nephritis, pulmonary inflammation and pulmonary fibrosis caused by the pulmonary inflammation, chronic liver disease and liver fibrosis caused by the chronic liver disease and the like.

The present invention relates a process for preparing a compound of Formula XX wherein: R1 is hydrogen, optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, alkoxy, aryloxy, alkenyloxy or alkynyloxy; R2 is an N-containign heterocyclyl or heteroaryl; and Q is optionally substitued aryl or heteroaryl. Furthermore a compound of the present invention are useful in the treamtment of various inflammatory, autoimmune and allergic diseases, such as method of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoartluitis, psoriatic arthritis, psoriasis, pulmonary fibrosis, wound healing disorders, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by the overexpression and over-activation of a matrix metalloproteinase using the compound.

Provided are alcohol amine derivatives, a preparation method therefor and the use thereof, and a drug for treating organ fibrosis or pulmonary inflammations caused by acute injury, belonging to the technical field of medicine. The alcohol amine derivatives have structures represented by formula R-1 or formula R-2 and are R-configuration compounds, and exhibit good therapeutic effects on organ fibrosis or pulmonary inflammations caused by acute injury. The results in the pharmacological embodiments show that the alcohol amine derivatives have excellent pharmaceutical effects both on pulmonary inflammations caused by acute injury and various types of organ fibrosis models, the pharmaceutical effects thereof being overall superior to that of S-configuration compounds and positive drugs Nintedanib and Pirfenidone.

The invention discloses application of KAT7 as a pulmonary fibrosis diagnosis and prognosis biomarker and a treatment target. The research finds that the lysine acetyltransferase KAT7 is remarkably up-regulated in lung tissues of human pulmonary fibrosis patients and mouse fibrosis models, and is mainly expressed in macrophages; kat7 is specifically knocked out from myeloid cells, so that lung inflammation and fibrosis processes of mice can be remarkably relieved; further research finds that the fibrosis promoting function of macrophages can be down-regulated by inhibiting the activity of KAT7, and the generation and deposition of collagen can be reduced. Research results of the invention reveal the key driving effect of KAT7 in pulmonary fibrosis, a new marker is provided for diagnosis and prognosis of pulmonary fibrosis, and a new target is provided for prevention and treatment of pulmonary fibrosis.

The invention provides a method for preparing inhalable targeted gold nanoparticles for accelerating pulmonary delivery and treating pulmonary inflammation. The method comprises the following steps: preparing plasmids; carrying out plasmid transformation; carrying out protein expression induction; carrying out protein purification; and the gold nanoparticles (Au (at) PEG-RBD NP) combined with the spikes RBD are prepared. Nanoparticles (NP) in air accumulate more readily in lungs with lipopolysaccharide-induced acute respiratory distress syndrome (ARDS) than in healthy lungs and enter alveolar epithelial cells that express angiotensin converting enzyme (ACE) 2 and L-SIGN (both are Spike receptors activated in ARDS hamsters). The nanoparticles (NP) treat tissue damage, oxidative stress, and inflammation more effectively than corticosteroids, and do not remain gold or create toxicity in the major organs one year after inhalation. The gold core can be used for inhibiting p38 alpha mitogen activated protein kinase and polo-like kinase 3. Similar therapeutic effects have been observed in hamsters suffering from hydrochloric acid induced ARDS. This self-therapeutic nanoparticle (NP), when combined with biomimetic and non-invasive delivery, provides a safe, efficient, and targeted treatment for lung inflammation.

According to various aspects of this disclosure, the present disclosure relates to a method for treating or reducing pulmonary inflammation and / or pulmonary fibrosis in a subject in need thereof comprising intramuscularly administering to the subject a recombinant adeno-associated virus (rAAV) vector. In some aspects, the rAAV vector comprises a vector genome and an AAV capsid (e.g., an AAV1 serotype). In some aspects, the vector genome comprises AAV inverted terminal repeats (ITRs) flanking an expression construct comprising a nucleotide sequence encoding a Fibroblast growth factor 21 (FGF21) or functional fragment thereof operably linked to a ubiquitous promoter.

This invention provides the use of a trisaccharide compound with a core structure of GlcN(1→4)IdoA(1→4)GlcNS in the preparation of a medicament for treating or preventing pulmonary fibrosis. This medicament can improve pulmonary inflammatory responses, reduce the degree of damage to lung tissue structure, improve or inhibit or delay the progression of pulmonary fibrosis, and ultimately improve and enhance pulmonary ventilation function in patients with pulmonary fibrosis.

The invention provides development and application of a mouse model for simulating pneumonia mononuclear-derived macrophage recruitment, and belongs to the technical field of biological medicine. A mouse expressing human ACE2 in the lung is constructed through an adeno-associated virus (AAV) carrier, then 2-3 mg / kg of spike protein is atomized to the lung through aerosolization, the modeling time is 3 days, and the process of novel coronavirus infection diseases can be better simulated. By focusing the index that mononuclear macrophages are infiltrated into the lung in quantity, the phenotype that mononuclear macrophages recruitment from the lung in pneumonia is successfully simulated on a mouse. The method is low in operation difficulty and simple in steps. The method has a good application prospect in the development of drugs for regulating / targeting mononuclear macrophage recruitment.

This invention relates to a mitochondrial composite nanosystem DTPS@Mito targeting lung inflammation, comprising a mitochondrial core and a functionalized lipid material DSPE-TK-PEG2000-SA modified on its surface. DSPE acts as a hydrophobic anchor inserted into the mitochondrial outer membrane, PEG2000 provides hydrophilicity and biocompatibility, ketithiothiol bonds serve as ROS-responsive linkers, and sialic acid targets the head group to specifically bind to E-selectin, which is highly expressed at the inflammatory site. The DTPS@Mito particles have a diameter of approximately 832 nm, maintaining intact mitochondrial morphology and protein composition. In vitro experiments show that it significantly inhibits the expression of inflammatory factors, reduces ROS levels, restores ATP production, and regulates mitochondrial dynamics. In vivo experiments show that it has enhanced retention and accumulation capacity in the lungs of ARDS mice, significantly alleviating lung inflammation, tissue damage, and oxidative stress, and reducing hyaline membrane formation. This invention achieves the synergistic integration of three major functions: mitochondrial transplantation, targeted delivery, and antioxidation, and can be used to prepare drugs for the treatment of acute respiratory distress syndrome.

The application provides an inflammation-targeting self-assembled nanoparticle and a preparation method and application thereof, and belongs to the technical field of biological medicines.The application uses HA as a targeting ligand, utilizes the NHS / EDC crosslinking reaction between the carboxyl group and the VP amine group to successfully construct an inflammation-targeting nanoparticle HA-VP@NPs.The nanoparticle inherits the advantages of the targeting combination of HA and CD44, can play the inhibiting effect of VP on inflammation, can effectively target the VP nanoparticle to the inflammation site in an inflammation environment, improves the efficiency of the delivery of VP to the inflammation site, improves the targeting of inflammation, and can effectively reduce the inflammation while reducing the toxic side effects of VP on normal tissues due to the weak targeting.The nanoparticle has good treatment effect on lung inflammation, and is also suitable for the treatment of related inflammation such as acute lung injury or acute respiratory distress syndrome.

This invention provides compounds of Formulae (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH), (IJ), (IK), (IL), (II), (III), (IIIA), and (IIIB); pharmaceutically acceptable salts and solvates thereof; and compositions thereof. This invention further provides methods for treating a disease, including but not limited to, liver disease or an abnormal liver condition; cancer (such as hepatocellular carcinoma or cholangiocarcinoma); a malignant or benign tumor of the lung, liver, gall bladder, bile duct or digestive tract; an intra- or extra-hepatic bile duct disease; a disorder of lipoprotein; a lipid-and-metabolic disorder; cirrhosis; fibrosis; a disorder of glucose metabolism; a cardiovascular or related vascular disorder; a disease resulting from steatosis, fibrosis, or cirrhosis; a disease associated with increased inflammation (such as hepatic inflammation or pulmonary inflammation); hepatocyte ballooning; a peroxisome proliferator activated receptor-associated disorder; an ATP citrate lyase disorder; an acetyl-coenzyme A carboxylase disorder; obesity; pancreatitis; or renal disease.

This invention provides a traditional Chinese medicine composition for treating and / or preventing lung inflammation-related diseases, wherein the herbal extract contains three active components: Scutellaria baicalensis extract, Stephania tetrandra extract, and Glycyrrhiza uralensis extract. This traditional Chinese medicine composition can be used to treat acute lung injury caused by various factors; currently, there is a lack of drugs for this disease in clinical practice, and this composition can fill that gap.

The invention discloses an acute respiratory distress syndrome (ARDS) prediction method and system based on multi-modal data and deep learning, relates to the technical field of computer-aided diagnosis, and provides a computer algorithm for intelligently predicting the severity of an ARDS patient based on computed tomography (CT) imaging and clinical indexes. Therefore, doctors can be assisted in early intervention and treatment. According to the technical key points, inflammation can be effectively segmented by using a 2.5 D U-Net model and a sub-visual recognition algorithm; according to the method, the ARDS is predicted by introducing an Extreme Graduent Boosting (XGBoost) algorithm after the segmented inflammation features are extracted, so that the ARDS prediction based on the imaging features is realized; the system can shorten the diagnosis time and reduce the death rate, and is of great significance to early diagnosis of ARDS. Experimental results show that the method provided by the invention has high accuracy in predicting the severity of the ARDS, the Dice coefficient of lung inflammation segmentation is 90.2%, and the accuracy of predicting the severity of the ARDS is 86.5%.

Described are methods of reducing pulmonary exacerbations and methods of treating cystic fibrosis, including methods of reducing pulmonary inflammation, comprising administration of an LTA4h inhibitor.

RNAi agents, compositions comprising RNAi agents, and methods for inhibiting thymic stromal lymphopoietin (TSLP) genes are described. The TSLP RNAi reagents and RNAi reagent conjugates disclosed herein inhibit the expression of the TSLP gene. Also described are pharmaceutical compositions comprising one or more TSLP RNAi agents, optionally in conjunction with one or more additional therapeutic agents. Delivery of the TSLP RNAi agents in vivo to lung cells provides inhibition of TSLP gene expression, which can provide therapeutic benefits to subjects, including human subjects, for the treatment of various diseases, including lung inflammatory diseases such as asthma, including allergic asthma.

The invention provides a bacillus cereus bacteriophage and application thereof, and belongs to the technical field of bacteriophages. The preservation number of the bacillus cereus phage provided by the invention is CCTCC (China Center For Type Culture Collection) NO: M 20251545. The bacteriophage provided by the invention can specifically split bacillus cereus and remarkably reduce the colonization amount of the bacillus cereus in the respiratory tract, so that lung inflammatory response caused by swine influenza virus infection is effectively relieved, lung tissue injury is reduced, infection symptoms are relieved, and remarkable interference on normal florae of a host is avoided. According to the technical scheme, a new direction is provided for development and utilization of the bacteriophage in the antiviral field, and compared with traditional antibiotics, the bacteriophage serving as a natural antibacterial agent has the advantages of precise targeting, self-replication, low toxicity and the like and has a wide application prospect in the aspect of prevention and treatment of influenza virus infection.

The application discloses a kind of based on recombinant IL-6 pneumonia model construction method and the application of pneumonia model.The pneumonia model construction method is:S1, to the lung of animal delivery recombinant IL-6 solution several days, establish animal pneumonia model;S2, to animal pneumonia model is carried out lung function evaluation and pathological evaluation, judge whether lung cancer model is successfully constructed.The method for constructing animal pneumonia model of the application is simple, easy to operate, and the time required for modeling is short.The animal pneumonia model of the application can simulate lung inflammatory diseases with IL-6 inflammatory factor up-regulation characteristics, proves that only IL-6 this inflammatory factor pulmonary administration can cause pneumonia, and provides a new animal model for mechanism research, prevention, diagnosis and treatment of pneumonia characterized by IL-6 elevation.

The application belongs to the technical field of medicine, and provides application of methylbadosolon in preparation of a medicine for inhibiting respiratory syncytial virus infection, and the application establishes an RSV infected cell and mouse model, observes pathological effects of BEAS-2B cells after infection of RSV by using an inverted microscope, detects cytotoxicity and antiviral effects of methylbadosolon by using a CCK8 method, detects RSV, IL-6, IL-8, IKKbeta and NF-kappa B mRNA expression by using a reverse transcription polymerase chain reaction, and detects RSV F, p-IKKbeta, p-NF-kappa B and IL-6 protein expression by using a Western blotting, for the first time, pharmacodynamics of methylbadosolon for relieving lung inflammation and injury caused by RSV infection through an IKKbeta / NF-kappa B pathway is confirmed, and methylbadosolon can be used for preparation of a medicine for inhibiting respiratory syncytial virus infection.

The present application relates to the application of etomoxir or its pharmaceutically acceptable salt in the preparation of a drug for preventing, improving or treating interstitial lung disease and related lung injury. The present application creatively finds that etomoxir and its pharmaceutically acceptable salt have excellent prevention and treatment effect on interstitial lung disease and related lung injury, which specifically shows that: it can effectively reverse the abnormal growth of lung index, lung function damage of interstitial lung disease mice induced by lipopolysaccharide or irradiation, improve the lung inflammation damage and the degree of pulmonary fibrosis of interstitial lung disease mice induced by lipopolysaccharide or irradiation. It provides a new strategy and theoretical basis for clinical prevention, improvement or treatment of interstitial lung disease.

The present invention relates to B-hydroxy and amino substituted carboxylic acide, which act as matrix metalloprotease inhibitor, particularly diastereomerically pure B-hydroxy carboxylic acid, corresponding processes for the synthesis of and pharmaceutical composition containing the compounds of the present invention. Compound of the present invention are useful in the treatment of various inflammatory, autoimmune and allergic diseases, such as methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriaasis, pulmonary fibrosis, wound healing disorders, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by the over-expression and over-activation of a matrix metalloproteinase using the compound.

The invention relates to the field of biological medicines, in particular to application of salicylic acid in preparation of a medicine for treating and / or preventing interstitial lung diseases. It is found that salicylic acid can significantly improve the lung function of mice with interstitial lung diseases, inhibit lung inflammation and reduce the fibrosis degree of lung tissue, and the activity of salicylic acid is better than that of acetylsalicylic acid and pirfenidone. The research result of the invention provides a theoretical basis for the application of salicylic acid in the treatment of interstitial lung diseases, and particularly discovers that the salicylic acid which is clinically applied but is limited to antipyretic, analgesic and anti-rheumatism can be applied to the inflammation and fibrosis of interstitial lung diseases and new application of old medicines, thereby providing a new strategy for the treatment of interstitial lung diseases.

The application relates to the field of biological medicine, and particularly relates to application of oxatomide in preparation of a medicine for preventing or treating acute lung injury. Oxatomide can reduce inflammation induced by lipopolysaccharide (LPS), and provides an alternative medicine for treating acute lung injury. Oxatomide can reduce inflammation induced by LPS in vivo or in vitro, and the reduction of inflammation includes significantly inhibiting lung inflammation induced by intratracheal administration of LPS, and significantly inhibiting production of inflammatory factors of macrophages induced by LPS.

The invention discloses an application of an exosome carrying miR-125a-5p in acute lung injury, and belongs to the technical field of biological medicines. The invention proposes that the miR-125a-5p and the human umbilical cord mesenchymal stem cell source carrying the miR-125a-5p exosome can be used for treating the acute lung injury for the first time; the miR-125a-5p and the human umbilical cord mesenchymal stem cell source carrying the miR-125a-5p exosome can improve the development process of the mouse acute lung injury by means of reducing lung microvascular endothelial cell ferroptosis, reducing expression of intercellular adhesion molecules and improving lung inflammation, and a new thought is provided for the pathogenesis of the acute lung injury. The research on related mechanisms of occurrence and development of the acute lung injury is further perfected. According to the invention, a theoretical basis and related experimental data support can be provided for clinical early diagnosis, early treatment and future development of targeted miRNA drugs and treatment of acute lung injury.

The invention relates to the field of medicines, in particular to application of Noregenin to treatment of acute lung injury or acute respiratory distress syndrome. According to the application disclosed by the invention, NLRP3 inflammasome activation and downstream inflammatory factor release are remarkably reduced by utilizing an inhibition effect of Noregenin on Nur77, so that lung inflammatory response, macrophage proinflammatory polarization and tissue damage in acute lung injury and acute respiratory distress syndrome are effectively relieved; and the pharmaceutical composition shows a definite lung protection effect in various dosage forms and administration modes.